India has reduced malaria cases dramatically, but the rise of drug‑resistant parasites threatens the goal of eliminating the disease by 2030. The article outlines recent gains, emerging challenges, and the steps needed to safeguard progress.
Key Developments
- Global malaria incidence fell by ~25% from 2000 to 2015, then rose 8.5% after 2015.
- India’s cases dropped from 6.4 million (2017) to ~2 million (2023), and deaths fell by 68%, moving the country from WHO’s High Burden to High Impact list.
- Door‑to‑door screening by ASHA workers and improved vector control were pivotal.
- Resistance to ACTs is emerging, especially in P. falciparum strains.
Important Facts
India’s malaria mix is about 57% P. falciparum and 43% P. vivax. The latter accounts for 46% of the global P. vivax burden and is notorious for relapses because dormant liver forms (hypnozoites) can reactivate.
Resistance to artemisinin is linked to mutations in the parasite’s K13 gene, such as the R561H variant first reported in Rwanda and now spreading across East Africa.
While these mutations have not become widespread in India, experts warn of a spill‑over risk. Melissa Sathyan and P. Praveen Kumar note growing concerns about reduced responsiveness of P. vivax to existing drugs.
Other drivers of resistance include misuse of medicines, poor adherence, counterfeit drugs, and historic use of artemisinin monotherapy. Insecticide resistance in vectors adds another layer of difficulty.
Exam Relevance
Understanding malaria dynamics touches several UPSC themes: public‑health policy (GS3), disease‑control programmes, health‑system strengthening, and the impact of climate change on vector‑borne diseases. The rise of Anopheles stephensi illustrates how environmental shifts can alter disease patterns, a frequent GS3 question.
The article also highlights the importance of surveillance mechanisms like therapeutic efficacy studies and molecular monitoring of K13 mutations, aligning with the Test‑Track‑Treat approach.
Way Forward
- Maintain and expand ASHA networks for early case detection.
- Strengthen drug‑quality assurance to curb counterfeit and sub‑standard medicines.
- Scale up molecular surveillance for K13 mutations and insecticide resistance.
- Introduce triple‑ACT regimens and rotate first‑line therapies in high‑risk zones.
- Deploy approved malaria vaccines in vulnerable districts.
- Invest in research for next‑generation anti‑malarial drugs and improved vector‑control tools.
Continued vigilance, community participation, and scientific innovation are essential to prevent drug resistance from eroding the hard‑won gains and to achieve the 2030 malaria‑free target.